Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Prospective Validation of the MASA Score for Detection of Previously Unknown Atrial Fibrillation (MASA-AF)

MASA (Metabolic-Atrial-Septal-Assessment) Score for Selecting Patients for Extended ECG Monitoring: A Prospective, Blinded, Single-Center Diagnostic Accuracy Cohort Study

The MASA (Metabolic-Atrial-Septal-Assessment) score is a simple 0-8 point score built from five routinely available variables: estimated glomerular filtration rate, serum triglycerides, absence of atrial septal aneurysm, left atrial diameter, and TAPSE. In a retrospective development cohort (n=246), a score of 5 or more identified patients with atrial fibrillation (AF). This prospective study will test, in consecutive patients with cardiovascular disease or stroke without known AF admitted to the Intensive Care Unit, whether a MASA score of 5 or more identifies those in whom AF is detected by continuous ECG monitoring. The score, its threshold, and the primary outcome are fixed before enrollment and will not be changed.

Panoramica dello studio

Stato

Non ancora reclutamento

Intervento / Trattamento

Descrizione dettagliata

Background: Undetected paroxysmal atrial fibrillation (AF) is a major preventable cause of stroke. Extended ECG monitoring is effective but resource-intensive; a simple score could help select patients who need it most.

Study phases: The study was approved by the Ethics Committee of the Special Hospital for Cerebrovascular Diseases "Sveti Sava" (No. 03/4310, 30 October 2026) under the title "Development of the MASA score for assessing the probability of atrial fibrillation in a retrospective cohort of cardiology patients and its prospective validation in the intensive care unit: a single-center study." Phase 1 (retrospective score development, n=246) is completed. This registration covers Phase 2, the prospective validation in consecutive patients with cardiovascular disease or stroke (ischemic stroke, hemorrhagic stroke, or transient ischemic attack) admitted to the Intensive Care Unit.

Pre-specified score (locked before enrollment): eGFR <60 mL/min/1.73 m² (CKD-EPI 2021) = 1 point; triglycerides <=1.2 mmol/L = 1 point; atrial septal aneurysm ABSENT on echocardiography = 3 points; left atrial diameter >=46 mm = 1 point; TAPSE <=17 mm = 2 points. Score range 0-8. Positive screen = score >=5.

Procedures: Consecutive eligible patients undergo blood sampling (serum creatinine, triglycerides) and transthoracic echocardiography (left atrial diameter, TAPSE, interatrial septum assessment) shortly after ICU admission, with heart rhythm recorded at the time of echocardiography. The MASA score is calculated by an investigator not involved in rhythm assessment. All patients, regardless of score, undergo continuous ECG monitoring during the ICU stay. ECG recordings are assessed by two readers blinded to the MASA score and its components; disagreements are resolved by a third reader. AF is defined as an episode of at least 30 seconds.

Sample size: At least 61 patients with confirmed AF are required for a precise estimate of sensitivity (target 100). Enrollment continues until at least 61 (target 100) patients with confirmed AF have been enrolled; the anticipated total enrollment is approximately 700 patients, assuming a 10% AF detection rate.

Analysis: Primary-sensitivity and specificity of MASA >=5 with 95% confidence intervals. Secondary-positive and negative predictive values, area under the ROC curve, comparison with age and CHA2DS2-VASc (DeLong test), decision curve analysis, and number of patients monitored per detected AF. Pre-specified sensitivity analysis: serum creatinine >=90 umol/L instead of eGFR. Reporting will follow STARD 2015 and TRIPOD+AI 2024.

Tipo di studio

Osservativo

Iscrizione (Stimato)

700

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

  • Nome: Dejan Munjiza, MD, MSc
  • Numero di telefono: +381608018437
  • Email: munjizad@gmail.com

Luoghi di studio

      • Belgrade, Serbia, 11000
        • Special Hospital for Cerebrovascular Diseases "Sveti Sava"

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

Consecutive adult patients with cardiovascular disease or stroke, without previously documented atrial fibrillation, admitted to the Intensive Care Unit of the Special Hospital for Cerebrovascular Diseases "Sveti Sava", Belgrade, Serbia.

Descrizione

Inclusion Criteria:

  • Age 18 years or older
  • Consecutive admission to the Intensive Care Unit with cardiovascular disease or stroke (ischemic stroke, hemorrhagic stroke or transient ischemic attack)
  • Sinus rhythm on the admission 12-lead ECG
  • Transthoracic echocardiography and blood tests (serum creatinine, triglycerides) feasible shortly after admission

Exclusion Criteria:

  • Any previously documented atrial fibrillation or atrial flutter
  • Atrial fibrillation or atrial flutter on the admission ECG
  • Permanent pacemaker or implantable cardioverter-defibrillator
  • Mechanical mitral valve prosthesis or moderate-to-severe mitral stenosis
  • Inadequate echocardiographic window for measurement of left atrial diameter, TAPSE or assessment of the interatrial septum
  • Expected duration of continuous ECG monitoring shorter than 24 hours

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Modelli osservazionali: COHORT
  • Prospettive temporali: PROSPECTIVE

Coorti e interventi

Gruppo / Coorte
Intervento / Trattamento
ICU patients with cardiovascular disease or stroke without known AF

Consecutive adult patients with cardiovascular disease or stroke (ischemic stroke, hemorrhagic stroke or transient ischemic attack), without previously documented atrial fibrillation, admitted to the Intensive Care Unit. All participants have the MASA score calculated and undergo continuous ECG monitoring during the ICU stay.

Calculation of the MASA score (range 0-8) from routinely collected data: eGFR <60 mL/min/1.73 m2 = 1 point; triglycerides <=1.2 mmol/L = 1 point; atrial septal aneurysm absent on echocardiography = 3 points; left atrial diameter >=46 mm = 1 point; TAPSE <=17 mm = 2 points. A score >=5 is considered a positive screen. The score does not influence patient management; all patients undergo continuous ECG monitoring regardless of score.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Sensitivity and Specificity of MASA Score >=5 for Detection of Atrial Fibrillation
Lasso di tempo: From ICU admission to ICU discharge (up to 30 days)

Sensitivity and specificity (with 95% confidence intervals) of a MASA score >=5 for atrial fibrillation detected by continuous ECG monitoring. Atrial fibrillation is defined as an episode lasting at least 30 seconds, confirmed by two readers blinded to the MASA score and its components; disagreements are resolved by a third reader.

From ICU admission to ICU discharge (up to 30 days)

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Positive and Negative Predictive Values of MASA Score >=5
Lasso di tempo: From ICU admission to ICU discharge (up to 30 days)

Positive and negative predictive values (with 95% confidence intervals) of a MASA score >=5 for atrial fibrillation detected by continuous ECG monitoring.

From ICU admission to ICU discharge (up to 30 days)
Discriminative Performance of the MASA Score
Lasso di tempo: From ICU admission to ICU discharge (up to 30 days)

Area under the ROC curve (with 95% confidence interval) of the MASA score for atrial fibrillation, compared with age and CHA2DS2-VASc score using the DeLong test.

From ICU admission to ICU discharge (up to 30 days)
Clinical Net Benefit of MASA-Guided Monitoring
Lasso di tempo: From ICU admission to ICU discharge (up to 30 days)

Net benefit of selecting patients for extended ECG monitoring by MASA score >=5, assessed by decision curve analysis.

From ICU admission to ICU discharge (up to 30 days)
Number of Patients Monitored per Detected Atrial Fibrillation
Lasso di tempo: From ICU admission to ICU discharge (up to 30 days)

Number of patients who would need extended ECG monitoring to detect one case of atrial fibrillation when monitoring is restricted to patients with MASA score >=5.

From ICU admission to ICU discharge (up to 30 days)

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Dejan Munjiza, MD, MSc, Special Hospital for Cerebrovascular Diseases "Sveti Sava"

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 dicembre 2026

Completamento primario (Stimato)

30 dicembre 2028

Completamento dello studio (Stimato)

30 giugno 2029

Date di iscrizione allo studio

Primo inviato

13 novembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

13 novembre 2026

Primo Inserito (Effettivo)

19 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

19 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

13 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

De-identified individual participant data underlying the published results, together with the analysis code, will be made available.

Periodo di condivisione IPD

After publication of the primary results, for at least 5 years.

Criteri di accesso alla condivisione IPD

Available to qualified researchers on reasonable request to the principal investigator, for non-commercial research purposes.

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • LINFA
  • CODICE_ANALITICO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi